Lipid management in the prevention of stroke: a meta-analysis of fibrates for stroke prevention

Zhou, Yu-Hao; Ye, Xiao-Fei; Yu, Fei-Fei; Zhang, Xiao; Qin, Ying-Yi; Lu, Jian; He, Jia

doi:10.1186/1471-2377-13-1

BMC Neurology

Table 3 Subgroup analysis for the effect of fibrates therapy on stoke, and fatal stroke

From: Lipid management in the prevention of stroke: a meta-analysis of fibrates for stroke prevention

	Group	Stroke event/total patients		Relative risk (RR)	P value	Heterogeneity	P value for heterogeneity
		Fibrates	Placebo
stroke	Published years
	after 2000	341/10062	351/10052	0.97 (0.84 to 1.13)	0.72	0%	0.51
	before 2000	292/8013	471/9664	1.06 (0.84 to 1.33)	0.63	52%	0.08
	Number of patients
	≥1000	573/17689	775/19332	0.99 (0.87, 1.12)	0.85	23%	0.26
	<1000	60/386	47/384	1.23 (0.80, 1.90)	0.34	30%	0.24
	Mean age
	<60	32/5331	27/5296	1.18 (0.71 to 1.96)	0.53	-	-
	≥60	405/11326	439/11319	0.93 (0.80 to 1.08)	0.34	17%	0.30
	Gender
	male	329/8749	498/10401	1.09 (0.86 to 1.38)	0.47	56%	0.06
	Male/female	304/9326	324/9315	0.95 (0.82 to 1.10)	0.48	0%	0.77
	Drug
	clofibrate	228/6749	383/8397	1.15 (0.98 to 1.34)	0.08	0%	0.59
	bezafibrate	132/2331	126/2327	1.05 (0.80 to 1.38)	0.37	21%	0.26
	gemfibrozil	64/1335	90/1339	0.72 (0.53 to 0.98)	0.04	0%	0.41
	fenofibrate	209/7660	223/7653	0.94 (0.78 to 1.13)	0.49	0%	0.49
	Control
	corn or olive oil	55/5378	49/5344	1.11 (0.80 to 1.54)	0.53	0%	0.76
	placebo	572/12697	761/14372	1.02 (0.88 to 1.17)	0.83	32%	0.17
	Follow-up
	≥60 months	421/12924	612/14575	1.01 (0.90 to 1.14)	0.85	0%	0.62
	<60 months	212/5151	210/5141	1.05 (0.76 to 1.46)	0.75	59%	0.05
	Total cholesterol
	≥6.0 mmol/L	228/6749	383/8397	1.15 (0.98 to 1.34)	0.08	0%	0.59
	<6.0 mmol/L	405/11326	439/11319	0.93 (0.80 to 1.08)	0.34	17%	0.30
	Total cholesterol lowering
	≥5%	409/12230	586/13890	1.04 (0.92 to 1.18)	0.49	0%	0.51
	<5%	173/3080	188/3073	0.98 (0.67 to 1.45)	0.93	71%	0.03
	Triglyceride lowering
	≥30%	101/1603	113/1603	0.96 (0.46 to 1.99)	0.92	74%	0.02
	<30%	477/11094	660/12769	1.02 (0.91 to 1.15)	0.69	0%	0.51
	Pre-exsistent diseases
	stroke	60/315	45/312	1.28 (0.86 to 1.90)	0.23	35%	0.22
	diabetes	209/7660	223/7653	0.94 (0.78 to 1.13)	0.49	0%	0.49
	other	364/10100	554/11751	1.00 (0.83 to 1.20)	0.99	36%	0.16
	Jadad score
	4	481/11575	699/13251	0.95 (0.82 to 1.09)	0.48	30%	0.22
	<4	152/6500	123/6465	1.22 (0.98 to 1.52)	0.07	0%	0.58
	Overall	633/18075	822/19716	1.02 (0.90 to 1.16)	0.78	27%	0.20
Fatal stroke	Published years
	after 2000	17/3548	17/3538	0.93 (0.33 to 2.60)	0.89	51%	0.15
	before 2000	24/6910	35/6875	0.70 (0.41 to 1.19)	0.18	0%	0.47
	Number of patients
	≥1000	34/10143	40/10101	0.82 (0.45 to 1.48)	0.51	32%	0.22
	<1000	7/315	12/312	0.59 (0.23 to 1.47)	0.26	0%	0.59
	Mean age
	<60	14/5331	14/5296	0.99 (0.47 to 2.08)	0.99	-	-
	≥60	20/4812	26/4805	0.69 (0.27 to 1.75)	0.44	53%	0.12
	Gender
	male	35/7646	39/7612	0.89 (0.53 to 1.51)	0.67	19%	0.30
	Male/female	6/2812	13/2801	0.46 (0.18 to 1.21)	0.12	0%	0.85
	Drug
	clofibrate	21/5646	26/5608	0.81 (0.45 to 1.44)	0.47	0%	0.59
	bezafibrate	13/783	9/785	1.45 (0.62 to 3.37)	0.39	-	-
	gemfibrozil	3/1264	9/1267	0.33 (0.09 to 1.23)	0.10	-	-
	fenofibrate	4/2765	8/2753	0.50 (0.15 to 1.65)	0.25	-	-
	Control
	corn or olive oil	16/5378	19/5344	0.85 (0.43 to 1.66)	0.63	0%	0.32
	placebo	25/5151	33/5141	0.73 (0.38 to 1.40)	0.34	30%	0.23
	Follow-up
	≥60 months	16/5378	19/5344	0.85 (0.43 to 1.66)	0.63	0%	0.32
	<60 months	25/5080	33/5069	0.73 (0.38 to 1.40)	0.34	30%	0.23
	Total cholesterol
	≥6.0 mmol/L	21/5646	26/5608	0.81 (0.45 to 1.44)	0.47	0%	0.59
	<6.0 mmol/L	20/4812	26/4805	0.69 (0.27 to 1.75)	0.44	53%	0.12
	Total cholesterol lowering
	≥5%	29/6161	28/6129	1.04 (0.62 to 1.76)	0.87	0%	0.38
	<5%	8/1532	16/1531	0.51 (0.22 to 1.20)	0.12	0%	0.40
	Triglyceride lowering
	≥30%	8/1532	16/1531	0.51 (0.22 to 1.20)	0.12	0%	0.40
	<30%	17/3548	17/3538	0.93 (0.33 to 2.60)	0.89	51%	0.15
	Pre-exsistent diseases
	stroke	7/315	12/312	0.59 (0.23 to 1.47)	0.26	0%	0.59
	diabetes	4/2765	8/2753	0.50 (0.15 to 1.65)	0.25	-	-
	other	30/7378	32/7348	0.91 (0.45 to 1.83)	0.78	42%	0.18
	Jadad score
	4	7/4029	17/4020	0.41 (0.17 to 1.00)	0.05	0%	0.66
	<4	34/6429	35/6393	0.97 (0.60 to 1.57)	0.91	0%	0.51
	Overall	41/10458	52/10413	0.79 (0.51 to 1.23)	0.30	6%	0.38

Back to article page

ISSN: 1471-2377

Contact us

General enquiries: journalsubmissions@springernature.com